LIVER FUNCTION TESTS AND STATINS

Size: px
Start display at page:

Download "LIVER FUNCTION TESTS AND STATINS"

Transcription

1 LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:

2 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated liver tests. Recent findings: As a result of the obesity epidemic in Western societies, conditions associated with metabolic syndrome are increasing NAFLD. Because most patients with metabolic syndrome have indications for statins, clinicians will be confronted with prescribing statins to patients with elevated liver tests. Statins are associated with elevations in aminotransferases in up to 3% of treated patients, but statins rarely lead to serious DILI, chronic liver disease, or acute liver failure. Data have emerged demonstrating that not only are statins well tolerated to use in most patients with elevated liver tests but also they may have a beneficial therapeutic effect in treating the underlying liver disease. Studies demonstrate that statins may increase response rates of antiviral therapy for hepatitis C. In a study of 437 patients with moderate elevations in baseline aminotransferases, patients on statins were more likely to have a decline in aminotransferases compared with untreated patients. Summary: Data support using statins in patients with elevated liver tests, especially patients with NAFLD, who may be at particularly high risk for cardiovascular disease.

3 Introduction Statins are among the most widely prescribed classes of medications, with > 130 million written in the USA in Obesity epidemic Hyperlipidemia & use of statins NAFLD: The most common cause of abnormal LFT in the western world. Have higher all-cause mortality than the general population. Frequently have other conditions associated with metabolic syndrome, including DM risk for cardiovascular disease. Diabetic + NAFLD High risk for cardiovascular disease and benefit from statins More likely to have elevated aminotransferases from NAFLD.

4 Introduction NAFLD + hyperlipidemia and other indications for lipidlowering therapy, clinicians are often faced with a perceived dilemma: Prescription of statins if the patient has elevated liver tests. The assumption that patients with underlying liver disease and elevated liver tests are predisposed to DILI may leave clinicians reluctant to prescribe statins when otherwise indicated. This review will focus on DILI associated with statins in patients with chronic liver disease. Data are compelling that not only are statins well tolerated to use in patients with chronic liver disease, but also in some types of chronic liver disease statins may have a beneficial effect on the underlying liver disease

5 Statins and drug-induced liver injury Aminotransferase elevations up to 3xULN Severe DILI is rare. The mechanism of DILI is not fully understood in rats given supratherapeutic doses of simvastatin (125 mg/kg / day) a suggested mechanism of toxicity is inhibition of the HMG-CoA reductase and mevalonate synthesis.

6 Serious DILI Jaundice (total BIL> 2xULN) after aminotransferase elevations. Hepatocellular jaundice from a drug had a 10% fatality rate. Severe DILI from statins are case reports or case series. In a systematic review of the literature, 40 cases of DILI from statins were identified among 26 Articles. The most common dose was 20mg daily, and time from initiation of therapy to DILI ranged from 1 week to 48 months. There were two cases of death, in which DILI from statins may have played a role.

7 Serious DILI Patterns of DILI of statins: Hepatocellular (The most common pattern) Cholestatic (can be seen) Mimicking autoimmune liver disease with the presence of autoantibodies, such as ANA. A retrospective study of the United Network for Organ Sharing (UNOS) database: Among patients who underwent liver transplant between in the United States, three cases were identified as having liver transplant for acute liver failure from statins. Two related to the use of cerivastatin, which has been subsequently withdrawn from the market (not for hepatotoxicity) One related to the use of simvastatin. These studies were retrospective analyses, and formal causality assessment of DILI and confirmation that cases were bona-fide cases of DILI from statins were not performed.

8 Serious DILI DILIN: Severe DILI is the focus of the DILI Network (DILIN), a multicenter prospective study of severe DILI from drugs other than acetaminophen. DILIN prospectively evaluates cases with formal causality assessment by expert hepatologists. Severe DILI: Aminotransferases > 5xULN or ALP > 2xULN or Total BIL >2.5 mg/dl associated with elevations in aminotransferases. Among 300 cases included in DILIN, 6 cases of statins were implicated as the single causative agent and in 5 cases statins were among multiple drugs implicated as a cause of DILI. Spanish Registry : Support that severe DILI from statins is rare. Given the vast number of prescriptions written for statins and the relatively small number of cases of DILI reported in these studies, severe DILI from statins appears to be an exceedingly rare event.

9 Statins and chronic liver disease NAFLD: The most common cause of abnormal LFT in the western world Present in up to 33% of American and European populations. The rise of NAFLD mirrors the obesity epidemic and overlaps with metabolic syndrome and DM. The spectrum of NAFLD: Hepatic steatosis only (not associated with significant progression of liver disease) Portal inflammation, sinusoidal fibrosis, and ballooning hepatocytes containing Mallory s hyaline (similar to alcoholic liver disease). Cirrhosis : Ballooning hepatocytes and fibrosis risk for cirrhosis. Cirrhosis and its complications (ascites, varices, and HCC) Risk for cardiovascular disease (particularly + DM). 69% higher all-cause mortality than the general population, (mainly due to cardiovascular disease.) Thus, NAFLD derive a significant clinical benefit from statin therapy.

10 Recent studies A recent post-hoc analysis of the Greek Atorvastatin and CHD Evaluation (GREACE) study : Atorvastatin in NAFLD + CAD cardiovascular events Elevated baseline aminotransferases 68% relative risk reduction of cardiovascular events in those who received a statin: 3.2 events per 100 patient years (statin group) versus 10.0 (nonstatin group), P= Reduction from baseline ALT, AST, and GGT in the statin group: 35, 47, and 46%, respectively. 10 patients on statins had ALT or AST levels > 3times the ULN 3 cases Normal with statin dose reduction from 80 40mg, suggesting a dose response relationship. 7 cases withdrew from the study due to DILI attributed to statin use, but there was no evidence of cholestatic (rise in BIL and/or ALP) liver injury None of the liver test elevations led to liver biopsy. Aminotransferases not exceed 3times the ULN in the GREACEstudy so the results may not be generalizable to patients with higher elevations in aminotransferases.

11 Recent studies Further evidence of the safety and efficacy of statins in patients with chronic liver disease was demonstrated in a RCT of pravastatin versus placebo. In a prospective double-blind study of 326 patients randomized to placebo or pravastatin 80mg daily, investigators examined the efficacy and safety of pravastatin in patients with well compensated liver disease. The cause of liver disease was NAFLD and HCV in 64 and 23% of patients, respectively. Fewer patients in the pravastatin group had elevations in ALT compared with the placebo group, 7.5 and 12.5%, respectively (P=0.13). No patient had to discontinue pravastatin due to elevations in liver tests. Pravastatin was effective in lowering total cholesterol and LDL with 16 and 25% reductions by week 36 of therapy.

12 Recent studies In a separate study of 68 patients with NAFLD, initiated statins reduction in the amount of steatosis in the statin group on serial liver biopsies: Statin group: 20% steatosis on baseline liver biopsy compared with 11% on follow-up liver biopsy, P= No statins group: not significant reduction in steatosis between baseline and follow-up liver biopsies. 24% of in the statin cohort had hepatic fibrosis progression compared with 45% in the no statin group. Noninvasive modalities that measure fat content in the liver, such as MRI with magnetic resonance spectroscopy, may facilitate future studies of the association between statins and hepatic steatosis.

13 Statins inhibit HCV replication and improve treatment response rates Sustained viral response undetectable HCV RNA in the serum 6 months after completion of antiviral therapy and considered a cure. In-vitro evidence : statins have antiviral properties against HCV by inhibiting HCV replication. (by disrupting host protein geranylgeranylation) Statin + PEG-IFN and ribavirin SVR rates SVR = 53% (statins + antiviral therapy ) SVR= 39% (antiviral only) P < Rao and Pandya analyzed data from the Veterans Affairs medical system Statin + Diabetic HCV patients Statistically significantly improved outcomes. On multivariate analysis 1.5 times more likely to have a SVR [OR 1.52 (95% CI ), P=0.0124] despite having higher viral loads, a negative predictor of response to therapy.

14 Table 1- Recent studies demonstrating safety and/or beneficial effect of statins in patients with chronic liver disease Study Purpose Statin Findings Athyros et al. [8] Rao and Pandya [9] Henderso n et al. [10] Hippisley- Cox and Coupland [11] Post-hoc analysis of 437 patients with elevated baseline liver tests enrolled in a randomized trial of atorvastatin Retrospective study VA database to evaluate HCV response rates in patients on statins Retrospective single center study of effect of statins on ALT in HCV patients Retrospective analysis of new statin users from large databases from England and Wales Mostly atorvastatin, simvastatin, pravastatin, fluvastatin Simvastatin (89%) Simvastatin, lovastatin SimvastatinA torvastatin, pravastatin, rosuvastatin fluvastatin Significant reduction in cardiovascular events in statin group versus no statin group, 10 versus 30%, P<0.0001, 35% reduction in ALT in statin group versus 12% increase in no statin group Diabetic patients on statins were 1.5 times more likely to have treatment response to antiviral therapy for hepatitis C, P= Although statin group had ALT 1.4 times higher than nonstatin group,65% had decline in ALT compared with 58% in no statin group ALT>120 IU/l was more commonly seen among smokers, DM, RA, corticosteroid users. Severe DILI not reported

15 Statin in cirrhosis Statins portal HTN and HCC. A double-blind RCT of simvastatin versus placebo: Simvastatin significantly decreased hepatic venous pressure gradient by a mean of 89.3% in cirrhosis. (independent of beta blocker use.) Because this was a proof-of concept study, it was not designed to assess overall liver mortality data. Simvastatin improved liver perfusion(assessed by measurement of hepatic wedged pressure and free hepatic venous measurements) There was no increase in statin-related hepatotoxicity in the treatment group as compared with the placebo group. Statin in cirrhosis Portal HTN morbidity and mortality from variceal hemorrhage

16 Statin and HCC HCC has been increasing in incidence worldwide, especially in patients with cirrhosis. A matched case control study: Nested within a cohort of diabetic patients A significant reduction in the incidence of HCC was seen in the group of patients who used statins versus in those who were not on statin therapy. Although there is not enough evidence to support the use of statins to prevent HCC, this large trial highlights the potential role of statins in cancer chemoprevention.

17 When statins should be avoided Avoided in : Acute viral hepatitis (such as acute hepatitis A and B) Autoimmune hepatitis flares If statins are indicated they should be initiated after resolution of the acute infection or control and remission of the underlying autoimmune disease. Alcoholic hepatitis, who may experience profound elevations in total bilirubin. Statins in cirrhosis: may require lower doses because may have greater exposure to the drug. Typically, advanced cirrhotics develop low cholesterol as their liver disease progresses.

18 Conclusion Statins were once thought to be contraindicated in patients with chronic liver disease but are now recommended. Given the overlap between chronic liver disease and cardiovascular risk factors, the indication for lipid-lowering therapy often arises. There is a lack of data to support serial monitoring of liver tests while on statin therapy, but typically patients with chronic liver disease have liver test monitoring for their underlying liver condition. Elevations in serum transaminases up to 3times the ULN or baseline are acceptable. Elevations in BIL> 2mg/dl may indicate potential severe liver dysfunction and should prompt the clinician to discontinue the statin. Recommend starting statins at lower doses, and titrating to the desired dose. Concomitant use of other medications that are metabolized by the CYP3A4 system should be prescribed cautiously. As the adage states, the benefits of statins clearly outweigh the risks in patients with chronic liver disease.

19 Key points Baseline liver tests should be obtained in patients with known chronic liver disease or risk factors for NAFLD before starting a statin. Statins are well tolerated to use in patients with elevations in aminotransferases. Statins may lower aminotransferases and improve liver histology in patients with NAFLD and may improve response rates to antiviral therapy for hepatitis C. Patients with acute hepatitis, alcoholic hepatitis, or decompensated cirrhosis may not be candidates for statins until the active condition resolves.

20

Statin Order. Disclosures 16/06/2016. The use of Statins in Chronic Liver Disease

Statin Order. Disclosures 16/06/2016. The use of Statins in Chronic Liver Disease Statin Order The use of Statins in Chronic Liver Disease Laura M. Stinton, MD MSc FRCPC Clinical Assistant Professor, University of Calgary Disclosures Advisory Board : Abbvie Clinical funding: Abbvie,

More information

Cirrhosis and HCV. Jonathan Israel M.D.

Cirrhosis and HCV. Jonathan Israel M.D. Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment

More information

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重

More information

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning

More information

HEPATITIS C DIAGNOSIS AND MANAGEMENT

HEPATITIS C DIAGNOSIS AND MANAGEMENT HEPATITIS C DIAGNOSIS AND MANAGEMENT Introduction The hepatitis C virus (HCV) is one of six viruses (A, B, C, D, E, G) that account for the majority of cases of viral hepatitis. It is responsible for about

More information

Non-alcoholic Fatty Liver Disease. Christi Matteoni, MD GI Consultants

Non-alcoholic Fatty Liver Disease. Christi Matteoni, MD GI Consultants Non-alcoholic Fatty Liver Disease Christi Matteoni, MD GI Consultants Definition of NAFLD Evidence of hepatic steatosis by imaging or histology No causes for secondary hepatic fat accumulation Significant

More information

Treatment and Management of NAFLD. Amanda Camp Wieland Fellow in Gastroenterology May 11, 2013

Treatment and Management of NAFLD. Amanda Camp Wieland Fellow in Gastroenterology May 11, 2013 Treatment and Management of NAFLD Amanda Camp Wieland Fellow in Gastroenterology May 11, 2013 Learning Objectives: Summarize the current epidemiology and natural history of Nonalcoholic Fatty Liver Disease

More information

Wendy Carter, DO Medical Officer Division of Antiviral Products, FDA

Wendy Carter, DO Medical Officer Division of Antiviral Products, FDA Wendy Carter, DO Medical Officer Division of Antiviral Products, FDA Click to view Biosketch and Presentation Abstract or page down to review presentation Evaluation of Transaminase Elevations in Subjects

More information

Alcoholic and Non-Alcoholic Fatty Liver Disease

Alcoholic and Non-Alcoholic Fatty Liver Disease Alcoholic and Non-Alcoholic Fatty Liver Disease Thomas W. Faust, M.D., M.B.E. Professor of Clinical Medicine Division of Gastroenterology The University of Pennsylvania Alcoholic Liver Disease Additional

More information

Who are the treatment populations?

Who are the treatment populations? The 2013 American Heart Association/American College of Cardiology (AHA/ACC) Guidelines utilize an evidence-based Clinical Question (CQ) approach. The AHA/ACC evidence-based format takes into account the

More information

Hypercholesterolemia Treatment

Hypercholesterolemia Treatment Hypercholesterolemia Treatment Screening As per the National Guideline Clearing House (NGC) and Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force (USPSTF) the recommended

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

HBV: Update and Treatment Guidelines

HBV: Update and Treatment Guidelines HBV: Update and Treatment Guidelines Virginia Clark, MD, MS Assistant Professor of Medicine Division of Gastroenterology, Hepatology, and Nutrition University of Florida Learning Objective Identify the

More information

Lipids: Understanding The New Prevention Guidelines

Lipids: Understanding The New Prevention Guidelines Lipids: Understanding The New Prevention Guidelines What you need to know J. Murray Estess MD Don t shoot the Messenger What has changed compared to ATP3 guideline? Initiate either moderate-intensity or

More information

Non-alcoholic Fatty liver disease in children. Dr.S.Venkatesh Karthik Consultant Paediatric Hepatologist KTP-NUCMI, NUH, Singapore

Non-alcoholic Fatty liver disease in children. Dr.S.Venkatesh Karthik Consultant Paediatric Hepatologist KTP-NUCMI, NUH, Singapore Non-alcoholic Fatty liver disease in children Dr.S.Venkatesh Karthik Consultant Paediatric Hepatologist KTP-NUCMI, NUH, Singapore Relevance Leading cause of chronic liver disease- both adults and children

More information

Abnormal Liver Tests and Fatty Liver Disease

Abnormal Liver Tests and Fatty Liver Disease Abnormal Liver Tests and Fatty Liver Disease Michael D Voigt MD Medical Director Liver Failure and Transplantation, University of Iowa Hospital and Clinics Conflict of interest: I sadly have nothing to

More information

L XI: DRUGS: 1. STATINS

L XI: DRUGS: 1. STATINS L XI: DRUGS: 1. STATINS Statins Classification Mechanism of action Pleiotropic effects Efficacy: -Lipid level -CV events Indications Aggressive lipid lowering Initiation and monitoring Toxicity and drug

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US

More information

Statin Safety: What Every Health Care Provider Needs to Know. Disclosures. Importance of Statin Safety 2/20/2015

Statin Safety: What Every Health Care Provider Needs to Know. Disclosures. Importance of Statin Safety 2/20/2015 Statin Safety: What Every Health Care Provider Needs to Know Carl E. Orringer, MD, FACC, FNLA Associate Professor of Medicine University of Miami Miller School of Medicine Disclosures Served on sitagliptin

More information

Statins and Primary Prevention in the Elderly What the HDL??? Sarah Earle November 21 st, Objectives

Statins and Primary Prevention in the Elderly What the HDL??? Sarah Earle November 21 st, Objectives Statins and Primary Prevention in the Elderly What the HDL??? Sarah Earle November 21 st, 2013 Objectives Screening Are we biased against older adults? Secondary Prevention Primary Prevention Treatment

More information

Quiz 2 Lipids summary statistics and answers. The correct answers to questions are indicated by *.

Quiz 2 Lipids summary statistics and answers. The correct answers to questions are indicated by *. 1 Quiz 2 Lipids summary statistics and answers The correct answers to questions are indicated by *. Quiz 2 score stats all students (n=163). 8.4±1.4,mean±sd 8.0, median 4.0-10.0, range n=163 (TC: 109,

More information

Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London

Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related

More information

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center

More information

NCEP Drug Treatment. Major Classes of Drugs Available Affecting Lipoprotein Metabolism

NCEP Drug Treatment. Major Classes of Drugs Available Affecting Lipoprotein Metabolism Major Classes of Drugs Available Affecting Lipoprotein Metabolism HMG CoA reductase inhibitors lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin cholestyramine, colestipol, colesevelam crystalline,

More information

HBV & HCV induced. Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences

HBV & HCV induced. Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences HBV & HCV induced Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences Definition of Cirrhosis Final pathway for a wide variety of chronic liver diseases

More information

Farris VAMC Farris VAMC 2015

Farris VAMC Farris VAMC 2015 New Guidelines for Cholesterol Overview Current cholesterol guidelines (ATP III) used at the VA New cholesterol guidelines presented in 2013 by the American College of Cardiology and the American Heart

More information

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School

More information

Fatty Liver Disease. Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director

Fatty Liver Disease. Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director Fatty Liver Disease Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director Icahn School of Medicine at Mount Sinai New York, NY Conflict of Interest Disclosure Having

More information

Liver cancer in HIV. Disclosures (last 1 year): Educational sessions sponsored by: Abbvie, Gilead

Liver cancer in HIV. Disclosures (last 1 year): Educational sessions sponsored by: Abbvie, Gilead Liver cancer in HIV David Wong, MD Toronto Centre for Liver Disease TGH Immunodeficiency Clinic SMH Positive Care Clinic www.torontoliver.ca www.facebook.com/torontoliver Disclosures (last 1 year): Educational

More information

New Treatments for Hepatitis B and C

New Treatments for Hepatitis B and C New Treatments for Hepatitis B and C Bradford Waters M.D. Associate Professor of Medicine, University of Tennessee, Memphis Memphis VA Medical Center Hepatitis B In adults 90-95% of acute hepatitis B

More information

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014 JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss

More information

GT-020 Phase 1 Clinical Trial: Results of Second Cohort

GT-020 Phase 1 Clinical Trial: Results of Second Cohort GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in

More information

Promacta. Promacta (eltrombopag) Description

Promacta. Promacta (eltrombopag) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 18, 2015 Promacta Description Promacta

More information

The following should be current within the past 6 months:

The following should be current within the past 6 months: EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,

More information

The Impact of Curing HCV

The Impact of Curing HCV The Impact of Curing HCV on the Liver and the Extra-hepatic ti Manifestation of Chronic HCV Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport

More information

THE SAFETY OF LOVASTATIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

THE SAFETY OF LOVASTATIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-211 THE SAFETY OF LOVASTATIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE L. NEDELCU 1 O. ANDREESCU

More information

Dr Lee Yin Mei Senior Consultant Gastroenterology NUHS

Dr Lee Yin Mei Senior Consultant Gastroenterology NUHS Dr Lee Yin Mei Senior Consultant Gastroenterology NUHS Simple steatosis (SS), through steatohepatitis Put picture of spectrum Prevalence of NASH 3-25% NASH Progression only occurs in NASH: 27% develop

More information

Review: How to work up your patient with Hepatitis C

Review: How to work up your patient with Hepatitis C Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

PIERO LUIGI ALMASIO CATTEDRA DI GASTROENTEROLOGIA UNIVERSITA OF PALERMO

PIERO LUIGI ALMASIO CATTEDRA DI GASTROENTEROLOGIA UNIVERSITA OF PALERMO Steatosi e Steatoepatite PIERO LUIGI ALMASIO CATTEDRA DI GASTROENTEROLOGIA UNIVERSITA OF PALERMO Alcoholic liver disease Liver damage resulting from long-term alcohol consumption Histological features:

More information

Strategy 2 was peginterferon alpha-2b (1.5 microg/kg per week subcutaneously) plus 800 mg/day ribavirin.

Strategy 2 was peginterferon alpha-2b (1.5 microg/kg per week subcutaneously) plus 800 mg/day ribavirin. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C Wong J B, Davis G L, McHutchison J G, Manns M P,

More information

LIVER TRANSPLANTION FOR NASH: Optimizing Post-Transplant Care. M. Shadab Siddiqui Virginia Commonwealth University November 14, 2016

LIVER TRANSPLANTION FOR NASH: Optimizing Post-Transplant Care. M. Shadab Siddiqui Virginia Commonwealth University November 14, 2016 LIVER TRANSPLANTION FOR NASH: Optimizing Post-Transplant Care M. Shadab Siddiqui Virginia Commonwealth University November 14, 2016 Objectives Trends in liver transplantation for NASH Mortality in liver

More information

IS VITAMIN E SAFE TO USE?

IS VITAMIN E SAFE TO USE? Vitamin E & Fatty Liver IS VITAMIN E SAFE TO USE? Nonalcoholic Fatty Liver Disease (NAFLD) & Nonalcoholic Steatohepatitis (NASH) Prevalence: 5.7-16.5% 57 5 in US Usually diagnosed in 40-60 y/o s Non-significant

More information

Session Outline 8/11/2015. Fatty Liver Disease. Conflict of Interest Disclosure

Session Outline 8/11/2015. Fatty Liver Disease. Conflict of Interest Disclosure Fatty Liver Disease Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director Icahn School of Medicine at Mount Sinai New York, NY Conflict of Interest Disclosure Having

More information

Alanine aminotransferase test

Alanine aminotransferase test Alanine aminotransferase test Also known as: Serum glutamic-pyruvic transaminase, SGPT or ALT The alanine aminotransferase test, also known as ALT, is one of a group of tests known as liver function tests

More information

Executive summary of recommendations

Executive summary of recommendations MOH CLINICAL PRACTICE GUIDELINES 2/2011 Chronic Hepatitis B Infection College of Family Physicians, Singapore Academy of Medicine, Singapore Singapore Medical Association Executive summary of recommendations

More information

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco

More information

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON

More information

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading

More information

Controversies in Primary Care: Treating Pre-Diabetes

Controversies in Primary Care: Treating Pre-Diabetes Controversies in Primary Care: Treating Pre-Diabetes Disclosures I have no disclosures regarding the content of this lecture today. Kevin J. Goist, MD Assistant Professor of Clinical Medicine Lead Physician,

More information

Statin Therapy An Update on Adverse Effects. Aaron Weisbord, MD, FACC South County Cardiology Division

Statin Therapy An Update on Adverse Effects. Aaron Weisbord, MD, FACC South County Cardiology Division Statin Therapy An Update on Adverse Effects Aaron Weisbord, MD, FACC South County Cardiology Division Introduction Statin use has been associated with many potential side effects. Statin intolerance rates

More information

Management of Complications of NASH: When to Biopsy? How to Treat? Assistant Professor University of Pittsburgh Medical Center.

Management of Complications of NASH: When to Biopsy? How to Treat? Assistant Professor University of Pittsburgh Medical Center. Management of Complications of NASH: When to Biopsy? How to Treat? Alison Jazwinski, MD, MHS Assistant Professor University of Pittsburgh Medical Center Clinical Case 31 yo female referred for evaluation

More information

First step: determine the goal for dyslipidemia treatment (primary prevention vs. secondary prevention)

First step: determine the goal for dyslipidemia treatment (primary prevention vs. secondary prevention) The American college of cardiology (ACC) and American Heart Association (AHA) in combination with National Heart, Lung and blood institute (NHLBI) have released 4 new guidelines. At the invitation of the

More information

News Release. Media Contacts:

News Release. Media Contacts: Media Contacts: Sheila Murphy Julia Miller Merck Edelman 514-428-2748 416-849-2996 sheila.murphy@merck.com julia.miller@edelman.com News Release Interim Phase II Data of Merck's Investigational MK-5172

More information

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf

More information

Evaluation and Prognosis of Patients with Cirrhosis

Evaluation and Prognosis of Patients with Cirrhosis Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded

More information

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia Guidelines

Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia Guidelines College of Pharmacy and Nutrition University of Saskatchewan Saskatoon SK S7N 5C9 www.medsask.usask.ca Vol. 31, No. 2 April 2014 Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia

More information

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

BACKGROUND MEDIA INFORMATION Fast facts about liver disease BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of

More information

Autoimmune Hepatitis. Hili N. Morillas, MD November 1, 2004 Morning Report

Autoimmune Hepatitis. Hili N. Morillas, MD November 1, 2004 Morning Report Autoimmune Hepatitis Hili N. Morillas, MD November 1, 2004 Morning Report Definition! An unresolving inflammation of unknown cause.! Characterized by the presence of interface hepatitis and portal plasma

More information

Prior Authorization Protocol ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin)

Prior Authorization Protocol ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Coverage of drugs is first determined by the member`s pharmacy or medical benefit.

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011

Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011 Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV

Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

Cardiovascular risk management: Current controversies

Cardiovascular risk management: Current controversies Cardiovascular risk management: Current controversies Medwise March 2014 Clinical Controversy Middle English controversie, from Anglo-French, from Latin controversia, from controversus strong disagreement

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information

Evaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH

Evaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH Evaluation of Liver Function tests in Primary Care Abid Suddle Institute of Liver Studies, KCH Liver Function tests Markers of hepatocellular damage Cholestasis Liver synthetic function Markers of Hepatocellular

More information

Non-alcoholic fatty liver disease (NAFLD): assessment and management

Non-alcoholic fatty liver disease (NAFLD): assessment and management Non-alcoholic fatty liver disease (NAFLD): assessment and management NICE guideline: short version Draft for consultation, December 0 This guideline covers assessing and managing non-alcoholic fatty liver

More information

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

2013 ACC/AHA Cholesterol Guidelines

2013 ACC/AHA Cholesterol Guidelines PL Detail-Document #300101 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 2013 ACC/AHA Cholesterol

More information

Could antiviral therapy reduce the incidence of HCC in patients with chronic hepatitis B? Hong You Beijing Friendship Hospital

Could antiviral therapy reduce the incidence of HCC in patients with chronic hepatitis B? Hong You Beijing Friendship Hospital Could antiviral therapy reduce the incidence of HCC in patients with chronic hepatitis B? Hong You Beijing Friendship Hospital Main Content Part 1 Natural progression history of hepatitis B disease and

More information

病 毒 性 肝 硬 化 的 台 大 醫 院 內 科 部 病 毒 性 肝 硬 化 的 治 療 方 針 C 型 肝 炎 導 致 的 肝 硬 化 (HCV-LC) 酒 精 性 肝 硬 化 脂 肪 肝 導 致 的 肝 硬 化 2013-1-9

病 毒 性 肝 硬 化 的 台 大 醫 院 內 科 部 病 毒 性 肝 硬 化 的 治 療 方 針 C 型 肝 炎 導 致 的 肝 硬 化 (HCV-LC) 酒 精 性 肝 硬 化 脂 肪 肝 導 致 的 肝 硬 化 2013-1-9 病 毒 性 肝 硬 化 的 治 療 方 針 台 大 醫 院 內 科 部 陳 健 弘 2013-1-9 病 毒 性 肝 硬 化 的 治 療 方 針 B 型 肝 炎 導 致 的 肝 硬 化 (HBV-LC) C 型 肝 炎 導 致 的 肝 硬 化 (HCV-LC) 酒 精 性 肝 硬 化 脂 肪 肝 導 致 的 肝 硬 化 1 Fibrosis score by pathology Histologic

More information

FORTH VALLEY. LIPID LOWERING GUIDELINES v4 May 2010

FORTH VALLEY. LIPID LOWERING GUIDELINES v4 May 2010 FORTH VALLEY LIPID LOWERING GUIDELINES v4 May 2010 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every

More information

MONITORING PATIENTS WHO ARE STARTING HEPATITIS C TREATMENT, ARE ON TREATMENT, OR HAVE COMPLETED THERAPY

MONITORING PATIENTS WHO ARE STARTING HEPATITIS C TREATMENT, ARE ON TREATMENT, OR HAVE COMPLETED THERAPY Published on Recommendations for Testing, Managing, and Treating Hepatitis C ( http://hcvguidelines.org) Home > MONITORING PATIENTS WHO ARE STARTING HEPATITIS C TREATMENT, ARE ON TREATMENT, OR HAVE COMPLETED

More information

Hepatitis C Testing Recommendations

Hepatitis C Testing Recommendations HEPATITIS WEB STUDY C Testing Recommendations Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist, Northwest AETC University

More information

Alcoholic Liver Disease

Alcoholic Liver Disease Alcoholic Hepatitis Paul Y. Kwo, MD Professor of Medicine i Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University School of Medicine 975 W. Walnut, IB 327 Indianapolis,

More information

Treatment of Hepatitis C in Patients With Cirrhosis

Treatment of Hepatitis C in Patients With Cirrhosis Treatment of Hepatitis C in Patients With Cirrhosis Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology Duke University School of Medicine Durham, North Carolina Disclosure Research grants Abbvie,

More information

Comparative Tolerability and Harms of Individual Statins

Comparative Tolerability and Harms of Individual Statins Comparative Tolerability and Harms of Individual Statins J.J.Brugts MD PhD MSc(1); H. Naci PhD MHS(2); T. Ades PhD(2) (1) Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands (2) London School

More information

Statins patient decision aid

Statins patient decision aid Statins patient decision aid What this decision aid is for This decision aid is intended to assist health professionals in consultations with patients in whom treatment with a statin is being considered,

More information

Dyslipidemia. Hisham Aljadhey, PharmD, PhD

Dyslipidemia. Hisham Aljadhey, PharmD, PhD Dyslipidemia Hisham Aljadhey, PharmD, PhD Etiology Primary hyperlipidemia Familial hypercholesterolemia Secondary hyperlipidemia Disease states: hypothyroidism, nephrotic syndrome, obesity, DM, alcoholism

More information

脂肪肝的西醫藥治療 Western medicine treatment on fatty liver. Vincent Wong 黃煒燊 Institute of Digestive Disease 消化疾病研究所

脂肪肝的西醫藥治療 Western medicine treatment on fatty liver. Vincent Wong 黃煒燊 Institute of Digestive Disease 消化疾病研究所 脂肪肝的西醫藥治療 Western medicine treatment on fatty liver Vincent Wong 黃煒燊 Institute of Digestive Disease 消化疾病研究所 Disclosures Advisory board member: AbbVie, Gilead, Janssen, Otsuka, Roche Consultancy: Merck,

More information

Hepatitis A, B, C. This material is intended for insurance informational purposes only and is not personal medical advice for clients.

Hepatitis A, B, C. This material is intended for insurance informational purposes only and is not personal medical advice for clients. Hepatitis A, B, C Hepatitis is a general term referring to inflammation of the liver. The usual cause is viral, either Hepatitis A, B, or C. However, toxins and drugs may also induce a hepatitis. The onset

More information

Update on hepatitis C: treatment and care and future directions

Update on hepatitis C: treatment and care and future directions Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New

More information

Alcoholic Hepatitis. Alexander Kuo, M.D. Associate Professor of Medicine Director, Hepatology and Liver Transplantation UC San Diego

Alcoholic Hepatitis. Alexander Kuo, M.D. Associate Professor of Medicine Director, Hepatology and Liver Transplantation UC San Diego Alcoholic Hepatitis Alexander Kuo, M.D. Associate Professor of Medicine Director, Hepatology and Liver Transplantation UC San Diego None Disclosures Learning Objectives Spectrum of alcoholic liver disease

More information

Alanine aminotransferase (serum, plasma)

Alanine aminotransferase (serum, plasma) Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Cholesterol Screening and Treatment in Adults Review of the 2013 AHA/ACC Cholesterol Guidelines (and a bit about kids)

Cholesterol Screening and Treatment in Adults Review of the 2013 AHA/ACC Cholesterol Guidelines (and a bit about kids) Cholesterol Screening and Treatment in Adults Review of the 2013 AHA/ACC Cholesterol Guidelines (and a bit about kids) Brian Waite, MD Keweenaw Medical Conference August 29, 2015 Cholesterol Bad Leading

More information

Fish Oil & Fatty Liver. Kittie Wyne, MD, PhD, FACE, FNLA SWLA Spring Clinical Update March 16, 2014

Fish Oil & Fatty Liver. Kittie Wyne, MD, PhD, FACE, FNLA SWLA Spring Clinical Update March 16, 2014 Fish Oil & Fatty Liver Kittie Wyne, MD, PhD, FACE, FNLA SWLA Spring Clinical Update March 16, 2014 Disclosures Speaker s Bureau: NovoNordisk, AZ Diabetes, Janssen Case 52 y/o WF is referred to you for

More information

HIGHLIGHTS FROM THE AASLD MEETING. Rob Goldin. Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk

HIGHLIGHTS FROM THE AASLD MEETING. Rob Goldin. Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk HIGHLIGHTS FROM THE AASLD MEETING Rob Goldin Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk What was on at the meeting? 1. Postgraduate Course 2. Oral Presentations 3. Poster

More information

Oxfordshire CCG Lipid Management Guidance Updated April Inside this issue: guidelines.

Oxfordshire CCG Lipid Management Guidance Updated April Inside this issue: guidelines. Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE CCG, JUBILEE HOUSE, OXFORD BUSINESS PARK SOUTH, OXFORD, OX4 2LH.

More information

Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests

Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests Christine Iannaccone, MPH, Michelle Frits, Jing Cui, PhD, Michael Weinblatt MD,

More information